A new study published in Diabetes Care found that automated insulin delivery (AID) systems lower A1C levels and increase time in the glucose range for adults with type 2 diabetes, regardless of their C-peptide levels.
Having a low C-peptide level should not be a prerequisite for AID therapy.
Researchers concluded that AID systems are beneficial for adults with type 2 diabetes, irrespective of C-peptide levels.
Author's summary: AID systems benefit type 2 diabetes patients.